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With the recent rise in the prevalence of obesity worldwide,
obesity-related albuminuria is now being recognized as a
critical risk factor for cardiovascular disease. However, there
is an urgent need for a better understanding of this
association. Recent clinical studies suggest that the adipocyte
hormone adiponectin may play a key role in the
development of obesity-related albuminuria. Moreover,
studies with the adiponectin knockout mouse indicate that
adiponectin can regulate podocyte function and thus
contribute to the initial development of albuminuria. Future
studies examining renal adipocyte cell biology are needed to
develop preventive and therapeutic strategies for
combatting the complications of obesity.
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It is well known that obesity is a risk factor for many medical
illnesses. Specifically, obesity has been associated with subtle
effects in the decline of kidney function and low-grade
albuminuria.1–4 Indeed, albuminuria is now considered as
one of the strongest risk factors for cardiovascular disease in
patients with obesity.5,6 However, it remains unclear how
obesity-related albuminuria develops and why a relationship
exists between albuminuria and cardiovascular morbidity
and mortality.
Several explanations may address these questions: (1)
There are common unmeasured factor(s) produced outside
the kidney that provide a link between albuminuria and the
risk for cardiovascular morbidity and mortality. (2) Factors
produced by the kidney in association or because of
albuminuria contribute to an overall cardiovascular risk.
(3) The relationship between albuminuria and cardiovascular
risk is a fortuitous relationship that belies an unknown factor
that is responsible for the risk and is independent of
albuminuria. The consensus widely quoted in medical
literature is that low-grade albuminuria is because of an
‘endothelial dysfunction’ and thus reflects a widespread
systemic vascular disturbance. However, the data to sup-
port endothelial dysfunction as the causative mecha-
nism of albuminuria in patients with obesity are largely
circumstantial.
Identifying the cell types involved in the association
between obesity and albuminuria may lead to an under-
standing of the relationship between albuminuria and
cardiovascular risk. Several key early studies that have
established a potential important relationship between
obesity and albuminuria may provide clues regarding the
potential cell types involved. It is well recognized that patients
with obesity may develop heavy proteinuria and a focal
segmental glomerulosclerosis syndrome.7 The characteristic
renal findings observed with obesity include glomerular
enlargement and a focal segmental sclerosis pattern.7,8 From
a nephrologist’s perspective, such a pattern of anatomical
abnormalities clearly suggests a role for podocytes. In a recent
study, weight reduction with bariatric surgery led to a
decrease in proteinuria, suggesting that a circulating factor
from adipocytes may play a role.9 Several animal models of
obesity have examined the effects on the glomerulus.
Although variable results on the kidney have been noted,
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a recent study in the C57Bl6 mouse strain showed that
feeding a high-fat diet led to the development of obesity,
large glomeruli, and albuminuria.10 Interestingly, mice fed a
high-fat diet exhibited hypoadiponectinemia and podocyte
foot process effacement. However, the mice also developed
insulin resistance and exhibited stimulation of a variety of
growth factors and inflammatory mediators, making it diffi-
cult to identify the mechanisms involved in the genesis of
albuminuria.
ADIPOCYTES AS AN ENDOCRINE ORGAN
A major conceptual breakthrough arose with the recogni-
tion that adipocytes are an active endocrine cell type.11,12
Adipocytes have now been shown to have an intact
renin–angiotensin system, and to secrete TNF-a, IL-6, PAI-
1, and TGF-b. These factors are clearly involved in a
paracrine or autocrine role in the enhancement of the
inflammatory phenotype of visceral adipocytes, likely in
concert with infiltrating macrophages. All these factors may
also act in an endocrine manner and lead to a podocyte and
endothelial dysfunction. In addition, adipocytes secrete
hormones that are specifically produced by adipocytes,
including leptin, adiponectin, and resistin.11,12 Leptin
production is associated with an increased size of adipocytes
and is positively correlated with body mass index. Leptin has
effects on appetite suppression, although hyperleptinemia is
commonly seen with obesity, and exogenous leptin does not
lead to consistent and profound weight loss. Leptin may have
direct effects on the kidney,13,14 although the specific leptin
receptors that mediate the effects of leptin have not been
clearly identified in renal cells. Resistin is a relatively
recently described adipokine that is linked to insulin
resistance in mice and humans.15 Resistin is increased with
obesity and may contribute to the kidney disease and
albuminuria associated with obesity.16 However, a mecha-
nistic role for resistin to mediate kidney disease has not
been established. Of the numerous factors that are regulated
with increased visceral obesity, only a few adipokines are
reduced with obesity. The best characterized of these is
adiponectin.
ADIPONECTIN
Adiponectin is a 30-kDa protein secreted by adipocytes and
exists as oligomers in the circulation. Adiponectin produc-
tion has been shown in other cell types such as cardio-
myocytes, but the predominant cell type responsible for
circulating adiponectin is the adipocyte. The human and
mouse adiponectin promoter contains binding sites for
sterol regulatory element-binding protein 1-c (SREBP-1c),
peroxisome proliferator-activated receptor gamma (PPARg),
CCAAT/enhancer-binding protein (C-EBP), as well as
E-boxes (CANNTG). SREBP-1c is increased with adipocyte
differentiation and is a positive upregulator of the adipo-
nectin gene. Id3 is a member of the family of inhibitor of
differentiation transcription factors and has been recently
found to inhibit adiponectin promoter activity by binding to
E47 (an E-box-binding protein) and preventing E47
augmentation of SREBP-induced adiponectin promoter
activation.17 The precise mechanism of reduced adiponectin
levels with obesity is unclear, although both inhibition
of gene expression as well as decreased secretion18 are
contributory.
Reduction of adiponectin levels is a consistent feature
among obese patients who have evidence of insulin resistance
and often go on to develop diabetes.19 Several studies have
shown that low adiponectin levels are associated with
increased long-term risk of cardiovascular disease.20,21
However, high adiponectin levels may also be associated
with increased cardiovascular disease and mortality.22,23
Adiponectin levels that decrease with obesity in mouse
models and measures of insulin resistance are improved with
exogenous adiponectin administration. Importantly, adipo-
nectin has been considered to have a vascular protective
effect, as it suppresses reactive oxygen species production in
a variety of cell types, including endothelial and cardio-
myocytes.24–26 The best-characterized receptors for adipo-
nectin are the AdipoR1 and AdipoR2 receptors.27 T-cadherin
has also been identified as a plasma membrane-binding
protein that binds adiponectin and may function as a
co-receptor. The AdipoR1 and R2 receptors are seven
transmembrane-spanning proteins, but are distinct from
the G-protein-coupled receptors (GPCRs) and do not
activate heterotrimeric G-proteins. In contrast to GPCRs,
the N-terminus of the adiponectin receptors is cyto-
plasmic and the C-terminus is extracellular. AdipoR1 is
present ubiquitously, whereas AdipoR2 is primarily expressed
in the liver. On the basis of studies with AdipoR1 and
AdipoR2 knockout mice, it has been found that AdipoR1 is
primarily responsible for activating adiponectin-induced
AMPK (AMP-activated protein kinase), whereas AdipoR2
mediates PPAR-a activation.28 Both receptors are required
for adiponectin-mediated insulin sensitivity. APPL1 (adaptor
protein containing a pleckstrin homology domain, phos-
photyrosine-binding domain (PTB), and leucine zipper
motif) is the first protein that has been identified to
bind directly to adiponectin receptors and seems to be
involved in the cross talk between adiponectin and insulin
signaling.29
ADIPONECTIN AND ALBUMINURIA
The potential link between adiponectin levels and low-grade
albuminuria was first identified in a clinical study,30 wherein
men with essential hypertension had a significant negative
correlation of adiponectin levels and low-grade albuminuria.
This clinical observation has now been replicated in obese
Japanese patients (males and females)31 and in our recent
study with obese male and female African Americans.32
However, similar to the bi-directional relationship of
adiponectin with cardiovascular disease (see above), there
are also reports showing a positive correlation between
adiponectin with high-grade albuminuria and declining
renal function.33,34 Nevertheless, the clinical data suggest
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that there could be a potential causative role for adipo-
nectin in the initial development of albuminuria in the
obese population.
To show a causative relationship of adiponectin with
albuminuria, we recently studied an adiponectin knockout
mouse32 and showed that the mice had baseline-increased
albuminuria (twice normal) with podocyte foot process
effacement. The endothelium appeared normal under
electron microscopy. Furthermore, podocytes expressed the
AdipoR1 receptor and adiponectin regulated an isoform of
NAPDH oxidase (Nox4) through the AMPK pathway.
Treatment of adiponectin knockout mice with adiponectin
normalized albuminuria and restored podocyte foot pro-
cesses. Adiponectin deficiency was also shown to be a
susceptibility factor for early diabetic kidney disease32 and
progressive non-diabetic renal disease in an independent
study.35
There are several implications of these studies. We can
now conclude that the podocyte is a key cell type involved in
the initial development of albuminuria and may play a
dominant role in the albuminuria associated with obesity.
The role of endothelial dysfunction may well be important
for albuminuria; however, definitive studies to document the
presence of glomerular endothelial dysfunction with low-
grade albuminuria have not been published. Furthermore,
the mechanisms of endothelial dysfunction that lead to
podocyte dysfunction have not been established.
That podocyte dysfunction can lead to endothelial
dysfunction has been well established; recent studies by
Quaggin’s group have shown that podocyte regulation of
VEGF can regulate endothelial function.36,37 Another im-
plication is that the adiponectin knockout mouse model may
serve to show that the initial development of albuminuria
involves podocytes and may be independent of the tubular
uptake of albumin. Further examination of the tubular
uptake of albuminuria in this model may help to resolve the
ongoing controversy38 as to whether the genesis of increased
albuminuria with obesity is primarily a podocyte phenotype
or a tubular cell phenotype. The regulation of podocyte
function by adiponectin also further establishes the ongoing
communication between adipocytes and renal cells.13,14 It
would be of great interest to examine the potential interactive
roles of adiponectin, leptin, and resistin in the development
of albuminuria and podocyte dysfunction.
A further implication of our studies is that there could
be a potential role for podocytes in the progression of
systemic vascular disease associated with albuminuria. Low
adiponectin levels could lead to a consequent increase in
Nox4 production by podocytes (Figure 1) and potentially
by other renal cell types. An increased Nox activity in the
kidney may contribute to the release of reactive oxygen
species from the kidney and potentially lead to a systemic
increase in reactive oxygen species and vascular injury. Thus,
the kidney could play an important contributory role in
the systemic vascular inflammation noted with obesity and
albuminuria.5
CONCLUSION
Owing to the rapid growth of obesity, a better understanding
of the risk factors for the complications of obesity is critical.
Now that albuminuria is recognized as perhaps the most
important risk factor for increased morbidity and mortality
in the obese population,5 a mechanistic understanding of the
development of albuminuria in the early stages of obesity is
necessary. It is likely that adiponectin plays an important
role. Hopefully, further research in adipocyte-renal cell
biology will lead to novel therapeutic approaches that
combat the increased morbidity and mortality associated
with obesity.
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